ABION’s ABN202 shows promise against ADC-resistant tumors in study
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
SEOUL, South Korea - ABION (KOSDAQ:203400) announced that its immuno-oncology candidate ABN202 demonstrated anti-cancer activity in preclinical studies comparing it with TROP2-targeting antibody-drug conjugates.
Read full article at source